CRISPR Therapeutics AG, a Switzerland-based pharmaceutical company, specializes in gene editing using CRISPR/Cas9 technology. With an ESG score of 25.4, the company is considered to have a medium risk assessment in the industry. Their groundbreaking technology, CRISPR/Cas9, allows for precise alterations in genomic DNA to treat genetically defined diseases. Their first approved drug, Casgevy, targets sickle cell disease and beta-thalassemia, addressing high unmet medical needs. CRISPR Therapeutics AG is also focusing on immuno-oncology and stem cell-derived therapy for Type 1 diabetes treatment. Discover the innovative world of gene editing with CRISPR Therapeutics AG.